title: Antinecrotic and antioxidant effects of superoxide dismutase during skin ischemia.
abstract: Antinecrotic activity of SOD was studied in rats with experimental skin ischemia. Treatment with SOD increased activity of endogenous SOD in skin homogenates (by 70 and 26% compared to the ischemic and intact skin, respectively). However, the rate of superoxide anion generation remained unchanged after SOD treatment. Creatine phosphate content and NAD/NADH redox potential increased by 16 and 21%, respectively, on day 3 after SOD administration. The increase in functional activity of the energy supply system and rise in the reserve capacity of the antioxidant protection system contribute to inhibition of lactate dehydrogenase and creatine phosphokinase and decrease in the cytolysis index under the influence of SOD. Our results indicate that SOD produces the antinecrotic effect and holds much promise for the therapy of skin ischemia.
authors.affiliation: Krasnodar Branch, Southern Bureau of the Russian Academy of Medical Sciences, Kuban State Medical University, Krasnodar.
authors.forename: V P
authors.initials: VP
authors.lastname: Galenko-Yaroshevskii
authors.forename: V V
authors.initials: VV
authors.lastname: Galka
authors.forename: O N
authors.initials: ON
authors.lastname: Stoyalova
authors.forename: A V
authors.initials: AV
authors.lastname: Agadzhanova
authors.forename: I V
authors.initials: IV
authors.lastname: Lapina
authors.forename: T V
authors.initials: TV
authors.lastname: Gaivoronskaya
authors.forename: L V
authors.initials: LV
authors.lastname: Popkova
authors.forename: I V
authors.initials: IV
authors.lastname: Churilova
authors.forename: A S
authors.initials: AS
authors.lastname: Gorelashvili
authors.forename: N A
authors.initials: NA
authors.lastname: Antelava
authors.forename: T M
authors.initials: TM
authors.lastname: Berberashvili
authors.forename: G V
authors.initials: GV
authors.lastname: Sukoyan
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001219:Aspartate Aminotransferases / Q000378:metabolism; D003402:Creatine Kinase / Q000037:antagonists & inhibitors; D007511:Ischemia / Q000473:pathology / Q000517:prevention & control*; D007770:L-Lactate Dehydrogenase / Q000037:antagonists & inhibitors; D008297:Male; D009336:Necrosis / Q000517:prevention & control; D051381:Rats; D012867:Skin / Q000098:blood supply* / Q000187:drug effects / Q000201:enzymology; D013482:Superoxide Dismutase / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D007770:L-Lactate Dehydrogenase; D013482:Superoxide Dismutase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase